

The effect of a specialized physiotherapy program in female patients with systemic sclerosis and inflammatory muscle disorders

Submission date 28/04/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 05/05/2021	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 24/05/2023	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Systemic sclerosis (scleroderma) is a long-lasting disease that affects your skin, connective tissue, and internal organs. It happens when your immune system causes your body to make too much of the protein collagen, an important part of your skin. As a result, your skin gets thick and tight, and scars can form on your lungs and kidneys.

Inflammatory myopathies are a group of diseases that involve chronic (long-standing) muscle inflammation, muscle weakness, and, in some cases, muscle pain. Myopathy is a general medical term used to describe a number of conditions affecting the muscles.

Scleroderma and idiopathic inflammatory myopathies (myositis) are rare chronic autoimmune diseases characterized by multiple organ involvement. Despite clinical improvement following pharmacotherapy, most patients develop a persistent disability that affects all aspects of life, including sexual function. Our study aims to investigate the effect of an 8-week, specialized physiotherapy program focused on the individual disease-specific musculoskeletal aspects that negatively impact sexual function.

Who can participate?

Female adults over 18 years of age, who fulfilled the 2013 EULAR/ACR classification criteria for systemic sclerosis or Bohan/Peter 1975 criteria for polymyositis/dermatomyositis

What does the study involve?

The intervention part includes 8 weeks of intensive supervised physiotherapy program that will be adapted to each patient's current health and functional status focused on the sexual function and quality of sexual life. Participants in both groups (intervention and control) will fill out several well-established and validated questionnaires assessing the sexual health, quality of life, level of disability, and presence of depression before and after the physiotherapy program.

What are the possible benefits and risks of participating?

Patients participating in the project can learn more about the impact of rheumatic diseases on sexual health, and those, who will be in the intervention group, can benefit from the opportunity

to try physiotherapeutic approaches to treat their sexual difficulties and movement disabilities. The only risk of taking part in the project is that physiotherapy will not improve patients' problems. It is very unlikely that physiotherapy could make the problem any worse or deteriorate patients' condition.

Where is the study run from?

Department of Rehabilitation in the Institute of Rheumatology in Prague (Czechia)

When is the study starting and how long is it expected to run for?

March 2019 to August 2021

Who is funding the study?

1. Grantová Agentura, Univerzita Karlova (Czechia)
2. Ministerstvo Školství, Mládeže a Tělovýchovy (Czechia)
3. Ministry of Health Czech Republic, Institute of Rheumatology

Who is the main contact?

Barbora Hermankova, hermankova@revma.cz

Contact information

Type(s)

Scientific

Contact name

Mrs Barbora Heřmánková

ORCID ID

<https://orcid.org/0000-0002-1314-1123>

Contact details

Na Slupi 450/4, Nové Město

Prague 2

Czech Republic

128 00

+420 (0)234 075 111

hermankova@revma.cz

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

The effect of an 8-week specialized physiotherapy program on sexual dysfunctions of female patients with systemic sclerosis and idiopathic inflammatory myopathies: a pilot study

Acronym

PHYS-SD-SSc/IIM

Study objectives

A specialized, 8-week, tailored physiotherapy program targetting the individual disease-specific musculoskeletal aspects that negatively impact the sexual function in patients with systemic sclerosis and idiopathic inflammatory myopathies improves the sexual function, pelvic floor function, disability, and quality of life (compared to controls treated with the standard of care).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 17/12/2019, Ethics Committee of the Institute of Rheumatology in Prague (Na Slupi 4, 128 50 Praha 2, Czech Republic; +420 234075244; putova@revma.cz), ref: 12898/2019

Study design

Interventional single-center prospective non-randomized controlled pilot study

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Systemic sclerosis/scleroderma, idiopathic inflammatory myopathies/myositis

Interventions

Control group: standard of care (i.e. standard pharmacological treatment according to the generally accepted recommendations on the management of systemic sclerosis, or idiopathic inflammatory myopathies, instructions for regular daily home exercise), no specific treatment for sexual dysfunctions.

Intervention group: standard of care (as described above) + 8 weeks of a specialized intervention program, twice a week, consisting of supervised physiotherapy (1 hour) focused on the individual disease-specific musculoskeletal aspects that negatively impact the sexual function.

All patients meeting the inclusion criteria (without any exclusion criteria) will be continuously addressed if they are willing to participate in the study, and based on their availability (social /family/employment duties, or commuting possibilities). Patients will be allocated to the intervention group based on their availability and willingness to adhere to the planned schedule. Those patients that will meet the inclusion criteria but will not be able to commute twice a week to Prague for physiotherapy for any reason (time reasons, living far away, not driving a car, and having difficulties showing up at scheduled times, do not want to undergo the program, but are willing to fill out questionnaires, etc.), will be included in the control group and only fill out

questionnaires at two-time points. The intervention will last 8 weeks. There is no follow-up period planned.

Intervention Type

Mixed

Primary outcome(s)

Measured at baseline and week 8:

1. Sexual function assessed with the Female Sexual Function Index questionnaire (FSFI) and the Brief Index of Sexual Functioning for Women questionnaire (BISF-W)
2. Quality of sexual life assessed by Sexual Quality of Life – Female questionnaire (SQoL-F)

Key secondary outcome(s)

Measured at baseline and week 8:

1. Health/disability assessed by Health Assessment Questionnaire questionnaire (HAQ)
2. Quality of life assessed by Medical Outcomes Short Form-36 questionnaire (SF-36)
3. Depression assessed by Beck's Depression Inventory-II questionnaire (BDI II)

Completion date

17/08/2021

Eligibility

Key inclusion criteria

1. An Independent Ethics Committee approved written Informed Consent form is signed and dated by the subject
2. Subject is considered reliable and capable of adhering to the protocol and visit schedule
3. Subject is female at least 18 years of age
4. Subject fulfilled the 2013 EULAR/ACR classification criteria for systemic sclerosis or Bohan /Peter 1975 criteria for polymyositis/dermatomyositis
6. Subject is regularly followed at our out-patient department and adheres to the standard-of-care pharmacological therapy indicated by his treating rheumatologist
7. Subject is willing to participate in the study and undergo all planned examinations
8. Subject reported low sexual function at least in two of three questionnaires assessing sexual function: Female Sexual Function Index (FSFI), Brief Index of Sexual Functioning for Women (BISF-W), Sexual Function Questionnaire (SFQ-28). Low sexual function in FSFI and SFQ-28 was established based on diagnostic cut-off scores, and in BISF-W, sexual dysfunction was determined based on the 15th percentile obtained from a comparison of healthy control scores of the same age

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Total final enrolment

12

Key exclusion criteria

1. Subject has any other condition, including medical or psychiatric, which in the investigator's judgment would make the subject unsuitable for inclusion in the study

Date of first enrolment

01/05/2021

Date of final enrolment

17/06/2021

Locations

Countries of recruitment

Czech Republic

Study participating centre

Institute of Rheumatology

Na Slupi 450/4, Nové Město

Prague

Czech Republic

128 00

Sponsor information

Organisation

Revmatologický Ústav

ROR

<https://ror.org/00jk0vn85>

Funder(s)

Funder type

University/education

Funder Name

Grantová Agentura, Univerzita Karlova [GAUK 1578119]

Alternative Name(s)

Grantová Agentura UK, Charles University Grant Agency, GA UK, GA, UK

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Czech Republic

Funder Name

Ministerstvo Školství, Mládeže a Tělovýchovy

Alternative Name(s)

The Ministry of Education, Youth and Sports, MŠMT, MŠMT, MEYS

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Czech Republic

Funder Name

Ministry of Health Czech Republic, Institute of Rheumatology [023728]

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to confidentiality.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Results article](#)

results

23/05/2023

24/05/2023

Yes

No